Efficacy and hypoglycaemia outcomes with once‐weekly insulin icodec versus once‐daily basal insulin in type 2 diabetes according to baseline glucagon‐like peptide‐1 receptor agonist and sodium‐glucose co‐transporter‐2 inhibitor use: A post hoc analysis of ONWARDS 1–5
Authors' conclusion
The efficacy and hypoglycaemia profile of icodec versus once-daily comparators was generally consistent across ONWARDS trials irrespective of background GLP-1RA and/or SGLT2i use.
Study context
- Population
- Individuals with T2D in ONWARDS 1–5, by baseline GLP-1RA and/or SGLT2i use
- Participants
- 3,765 individuals5 RCTs
- Comparison
- Once-weekly insulin icodec vs once-daily basal insulin comparators
Methodological detailssubgroup analysis by baseline GLP-1RA and SGLT2i use
- Subgroup analysis by baseline GLP-1RA and SGLT2i use
Primary result
As reported in the abstract
Treatment effects by GLP-1RA or SGLT2i subgroups · baseline to end of treatment
- No statistically significant treatment interactions by GLP-1RA or SGLT2i subgroups for change in HbA1c and body weight (except body weight change by SGLT2i use in ONWARDS 5)
- No statistically significant treatment interactions for weekly basal insulin dose during last 2 weeks (except SGLT2i use in ONWARDS 5)
- No statistically significant treatment interactions for achievement of HbA1c <7% without clinically significant or severe hypoglycaemia
- Post hoc analysis
Further findings
Baseline GLP-1RA and SGLT2i use at screening
- Treated with a GLP-1RA
- 21.3% (801/3765)
- Treated with an SGLT2i
- 36.9% (1388/3765)
- GLP-1RA users had numerically higher BMI than non-users
Safety
Clinically significant or severe hypoglycaemia
- Rates irrespective of GLP-1RA/SGLT2i use were less than one episode per patient-year of exposure across all trials except ONWARDS 4 (basal-bolus trial)
Original publication
Efficacy and hypoglycaemia outcomes with once‐weekly insulin icodec versus once‐daily basal insulin in type 2 diabetes according to baseline glucagon‐like peptide‐1 receptor agonist and sodium‐glucose co‐transporter‐2 inhibitor use: A post hoc analysis of ONWARDS 1–5. Diabetes Obes Metab. Published 17 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →